MedTrace Logo

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

NCT04882449 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 329

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.

Conditions

Interventions

DEVICE

Bodyport Cardiac Scale

The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.

Sponsors & Collaborators

  • Duke Clinical Research Institute

    collaborator OTHER

  • Bodyport Inc.

    lead INDUSTRY

Principal Investigators

  • Adam Devore, MD · Duke Clinical Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2023-04-30
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04882449 on ClinicalTrials.gov